Comparison tool

Matrixyl 3000 vs GHK-Cu side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

Matrixyl 3000GHK-Cu

Share this peptide comparison

Property	Matrixyl 3000	GHK-Cu
Category	Skin & Hair	Skin & Hair
Also known as	Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7, Pal-GHK, Pal-GQPR	Copper Peptide, Glycyl-L-histidyl-L-lysine copper
FDA approved	No	No
Clinical status	Cosmetic use - Widely available Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Used in cosmetic products with limited human topical-skincare evidence; the source also notes injectable compounding restrictions and a pending reclassification process. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Advanced anti-aging, collagen synthesis, skin repair	Skin rejuvenation, wound healing, hair growth, anti-aging
How it works	Matrixyl 3000 is presented as a palmitoylated matrikine complex. Palmitoyl tripeptide-1 is reported to signal fibroblasts toward production of extracellular-matrix proteins including collagen, elastin, and fibronectin. Palmitoyl tetrapeptide-7 is described as acting on inflammatory signaling by reducing IL-6, a cytokine associated in the source with age-related matrix degradation and possible collagen glycation damage. The lipid attachments are included to help the otherwise water-soluble peptides pass into the skin when applied topically.	GHK-Cu is described as the copper(II) complex of the GHK tripeptide. The source connects its activity to copper binding and possible cellular copper delivery, but also emphasizes effects that go beyond a simple carrier model. Reported laboratory observations include shifts in gene expression, increased fibroblast production of extracellular-matrix components, keratinocyte support, vascular-related activity, and antioxidant or anti-inflammatory signals. The precise mechanism is still not fully defined.
Typical dosing	Limited community data available · See research protocols	1-2 mg daily injection or 0.05% topical · Once daily · Subcutaneous injection or topical application
Research dosing	2-8% in formulations · Ongoing use for maintained effects · Topical (serums, creams)	1-2 mg for injectable protocols · Varies by application · Subcutaneous injection or topical application
Typical duration	Ongoing use for maintained effects	Varies by application
Administration	Topical (serums, creams)	Subcutaneous injection or topical application
Timing	Morning or as directed With or without food	Evening for skin or recovery contexts With or without food
Evidence level	Research	Clinical Trials
Possible side effects	Generally very well-tolerated (Reported as generally well tolerated in the source.) Temporary stinging (Reported during the first week.) May trigger breakouts in acne-prone skin (Listed as a possible response for acne-prone skin.) +1 more Avoid mixing with strong acids (Source-supported topical compatibility caution.)	Generally well tolerated (Reported as a general tolerability statement in the source.) Mild topical irritation, redness, or tingling (Associated with topical use.) Injection-site reactions (Associated with injectable use.) +4 more Possible histamine release (Source advises caution for MCAS or histamine sensitivity.) Copper toxicity risk with excessive use (Risk described for excessive exposure.) Wilson's disease contraindication (Source lists Wilson's disease as contraindicated.) Caution with active cancer (Source flags an angiogenesis-related concern.)
Research summary	The supplied research summary describes Matrixyl 3000 as biologically plausible, with in vitro findings for its components that include fibroblast proliferation, synthesis of collagen types I, III, IV, and VII, and IL-6 reduction by the tetrapeptide. It also cautions that commonly cited 12-week reports for wrinkles and skin laxity are largely manufacturer-originated or sponsored, while large independent placebo-controlled studies focused on this exact complex are described as sparse. The source states that stronger independent evidence in this peptide family is associated with the original Pal-KTTKS Matrixyl data. The expected area of interest is skin texture and firmness rather than muscle-relaxing effects.	The source describes a mixed evidence base. Cell and animal work is reported for wound repair, collagen deposition, fibroblast activity, elastin and growth-factor production, keratinocyte protection, and lung-injury models. Human data are described as small topical cosmetic studies, including facial-cream and eye-cream studies with 71 and 41 participants that reported changes in skin density, thickness, and wrinkle appearance. These data are encouraging for topical skin endpoints but do not establish injected or systemic benefits.
References	Source Source +1 more Source	PubMed PubMed +1 more PubMed
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Matrixyl 3000

GHK-Cu

Category

Skin & Hair

Also known as

Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7, Pal-GHK, Pal-GQPR

Copper Peptide, Glycyl-L-histidyl-L-lysine copper

FDA approved

Clinical status

Cosmetic use - Widely available

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Used in cosmetic products with limited human topical-skincare evidence; the source also notes injectable compounding restrictions and a pending reclassification process.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Advanced anti-aging, collagen synthesis, skin repair

Skin rejuvenation, wound healing, hair growth, anti-aging

How it works

Matrixyl 3000 is presented as a palmitoylated matrikine complex. Palmitoyl tripeptide-1 is reported to signal fibroblasts toward production of extracellular-matrix proteins including collagen, elastin, and fibronectin. Palmitoyl tetrapeptide-7 is described as acting on inflammatory signaling by reducing IL-6, a cytokine associated in the source with age-related matrix degradation and possible collagen glycation damage. The lipid attachments are included to help the otherwise water-soluble peptides pass into the skin when applied topically.

GHK-Cu is described as the copper(II) complex of the GHK tripeptide. The source connects its activity to copper binding and possible cellular copper delivery, but also emphasizes effects that go beyond a simple carrier model. Reported laboratory observations include shifts in gene expression, increased fibroblast production of extracellular-matrix components, keratinocyte support, vascular-related activity, and antioxidant or anti-inflammatory signals. The precise mechanism is still not fully defined.

Typical dosing

Limited community data available · See research protocols

1-2 mg daily injection or 0.05% topical · Once daily · Subcutaneous injection or topical application

Research dosing

2-8% in formulations · Ongoing use for maintained effects · Topical (serums, creams)

1-2 mg for injectable protocols · Varies by application · Subcutaneous injection or topical application

Typical duration

Ongoing use for maintained effects

Varies by application

Administration

Topical (serums, creams)

Subcutaneous injection or topical application

Timing

Morning or as directed

With or without food

Evening for skin or recovery contexts

With or without food

Evidence level

Research

Clinical Trials

Possible side effects

Generally very well-tolerated (Reported as generally well tolerated in the source.)
Temporary stinging (Reported during the first week.)
May trigger breakouts in acne-prone skin (Listed as a possible response for acne-prone skin.)

+1 more

Avoid mixing with strong acids (Source-supported topical compatibility caution.)

Generally well tolerated (Reported as a general tolerability statement in the source.)
Mild topical irritation, redness, or tingling (Associated with topical use.)
Injection-site reactions (Associated with injectable use.)

+4 more

Possible histamine release (Source advises caution for MCAS or histamine sensitivity.)
Copper toxicity risk with excessive use (Risk described for excessive exposure.)
Wilson's disease contraindication (Source lists Wilson's disease as contraindicated.)
Caution with active cancer (Source flags an angiogenesis-related concern.)

Research summary

The supplied research summary describes Matrixyl 3000 as biologically plausible, with in vitro findings for its components that include fibroblast proliferation, synthesis of collagen types I, III, IV, and VII, and IL-6 reduction by the tetrapeptide. It also cautions that commonly cited 12-week reports for wrinkles and skin laxity are largely manufacturer-originated or sponsored, while large independent placebo-controlled studies focused on this exact complex are described as sparse. The source states that stronger independent evidence in this peptide family is associated with the original Pal-KTTKS Matrixyl data. The expected area of interest is skin texture and firmness rather than muscle-relaxing effects.

The source describes a mixed evidence base. Cell and animal work is reported for wound repair, collagen deposition, fibroblast activity, elastin and growth-factor production, keratinocyte protection, and lung-injury models. Human data are described as small topical cosmetic studies, including facial-cream and eye-cream studies with 71 and 41 participants that reported changes in skin density, thickness, and wrinkle appearance. These data are encouraging for topical skin endpoints but do not establish injected or systemic benefits.

References

+1 more

+1 more

Full profile